Researchers at University of California San Diego School of Medicine found using blood thinners in patients with worsening heart failure, coronary artery disease and irregular heart rhythms was associated with a reduced risk of thromboembolic events, such as stroke and heart attack.
UC San Diego researchers report that one kind of perceptual learning can occur in memory-impaired persons who do not actually remember what they learned.
UC San Diego researchers report that conducting genomic evaluations of advanced malignancies can be effective in guiding first-line-of-treatment, rather than waiting until standard-of-care therapies have failed.
Diagnoses of autism spectrum disorder (ASD) by trained professionals in children as young as 14 months are remarkably stable, suggesting that accurate screening and earlier treatment is feasible, report scientists at University of California San Diego School of Medicine.
UC San Diego School of Medicine research sets the stage for clinicians to potentially one day use levels of a pancreatic cancer patient’s PHLPP1 and PKC enzymes as a prognostic, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the…
The UC San Diego Autism Center for Excellence has received a $1.5 million gift from Kristin Farmer, founder and chief executive officer of ACES, a company that provides services to children with autism and their families, to support the work of Karen Pierce, co-director of the Autism Center.
With support from Amazon Web Services, UC San Diego Health physicians are using AI in a clinical research study aimed at speeding the detection of pneumonia, a condition associated with severe COVID-19.
Researchers at University of California San Diego School of Medicine, as well as a diverse team of cardiologists and physicists, developed a machine learning algorithm to predict the life expectancy in heart failure patients.
Researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval.
UC San Diego Health has launched a Phase III clinical trial to assess whether a medication used to treat rheumatoid might also have therapeutic value for patient with COVID-19 who have developed or are at high risk of developing serious lung damage from SARS-CoV-2 infections.
Health Media Contacts
Find the best contact for health-related media inquiries.
